Ravulizumab in Pregnancy Shows No New Safety Signals in Global Analysis
A global pharmacovigilance analysis of 354 pregnancies found no unexpected safety signals with the complement inhibitor ravulizumab, with outcomes consistent ...
A global pharmacovigilance analysis of 354 pregnancies found no unexpected safety signals with the complement inhibitor ravulizumab, with outcomes consistent ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.